Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026
Achieve Life Sciences (Nasdaq: ACHV) will report fourth quarter and full year 2025 financial results and provide a corporate update on its cytisinicline development program on March 24, 2026 at 8:30 AM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Achieve Life Sciences (Nasdaq: ACHV) will report fourth quarter and full year 2025 financial results and provide a corporate update on its cytisinicline development program on March 24, 2026 at 8:30 AM EDT.
Investors can access a live webcast, join the conference call (877-269-7756 U.S. & Canada; 201-689-7817 International; conference ID 13758715), and view a replay posted about three hours after the call that will be archived for 90 days.
Details
News Market Reaction – ACHV
On Mar 17, the day this news came out, ACHV closed 1.19% above the previous close.
Data tracked by StockTitan Argus for the Mar 17 session.
Key Figures
- Shelf registration amount
- $300,000,000
- Form S-3 shelf filed 2026-01-23
- Franklin ownership
- 6,369,193 shares (11.5%)
- Schedule 13G/A as of 2025-12-31
- Warrant shares
- 2,000,000 shares
- Included in Franklin’s reported beneficial ownership
- Franklin Biotech Fund stake
- 4,094,440 shares (7.4%)
- Part of overall Franklin position
- CEO stock options
- 645,000 shares
- Option grant at $4.36 exercise price, expires 2036-01-28
- C-suite option grants
- 180,000 shares each
- Options granted to multiple executives at $4.36 per share
- Current share price
- $4.20
- Before earnings date announcement
- 52-week range
- $1.84 – $6.03
- Low and high prior to this news
Historical Context
-
Pooled Phase 3 cytisinicline data and ORCA-OL experience presented at SRNT.
-
New-hire stock options totaling 115,000 shares under 2024 Equity Inducement Plan.
-
Promotion of Dr. Mark Rubinstein to Chief Medical Officer amid progress on milestones.
-
Planned one-on-one meetings during J.P. Morgan Healthcare Conference week.
-
Inducement stock options for new hires including Chief Legal Officer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT.
To access the webcast, please use the following link: 4Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID 13758715. A webcast replay will be available approximately three hours after the call and archived on the website for 90 days.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.
About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than
In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.1 In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes.4 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed as a treatment of nicotine dependence for smoking cessation and has not been approved by the FDA for any indication in the United States.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, and the successful commercialization of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
425-686-1510
References
1National Center for Health Statistics. National Health Interview Survey, 2023 and 2024. 2026 (https://www.cdc.gov/nchs/nhis.htm).
2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
3U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
4Jamal A, Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–924.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.